Suchergebnisse

Depuis dix ans, le développement de la médecine de précision bouscule la prise en charge du cancer. Pour autant, ces nouveaux traitements restent essentiellement disponibles via la participation à des essais cliniques. Cet article s'intéresse donc aux inégalités sociales d'accès aux essais précoces en cancérologie, question jusque-là peu investiguée. Ce travail s'appuie sur une méthodologie mixte associant données qualitatives (entretiens semi-directifs et observations) et quantitatives (enquête nationale auprès de 1 355 patients inclus). L'analyse croisée de ces données met au jour l'existence d'inégalités d'ordre social (genre), organisationnel (parcours de soin) et géographique. Ces inégalités s'illustrent dès les premières étapes de la prise en charge autour de trois mécanismes : l'organisation des filières d'accès aux essais, le tri des patients en amont de l'inclusion et les contraintes liées à la participation à un protocole de recherche.

During the COVID-19 pandemic, public debates overtly addressed the promises of new innovative treatments. Many of these debates pitted those who advocated for the development of new treatments by pharmaceutical companies against those who favored the repositioning of existing drugs. Our study explored perceptions of the association between drug novelty and effectiveness as well as perceptions of the role of the pharmaceutical industry in drug development. Data were collected in January 2021 from a quota sample of the French population aged 18–75 years (N = 1,000) during the second round of the "Health Literacy Survey 2019" (HLS19). We tested the hypothesis that individuals with a high level of familiarity with the health care system and those with a high level of trust in institutions are more likely to agree that new drugs are more effective than old ones and that drug development should be driven by the pharmaceutical industry. A quarter (25%) of respondents agreed that new drugs are always more effective than old ones. Agreement with this statement was stronger among respondents with a high level of familiarity with the health care system (as measured by the Navigational Health Literacy score, OR 3.34 [2.13-5.24]) and among those with a high level of trust in pharmaceutical companies or politicians. A high level of trust in pharmaceutical companies was reported by 42% of respondents, and 43% agreed that drug development should be driven by the pharmaceutical industry. Respondents who agreed that new drugs are always more effective than old ones were almost four times more likely to agree that drug development should be driven by the pharmaceutical industry (OR 3.85 [2.76-5.39]). A better understanding of public attitudes towards new treatments is needed to elucidate individual preferences in health care and their consequences on health behavior.

During the COVID-19 pandemic, public debates overtly addressed the promises of new innovative treatments. Many of these debates pitted those who advocated for the development of new treatments by pharmaceutical companies against those who favored the repositioning of existing drugs. Our study explored perceptions of the association between drug novelty and effectiveness as well as perceptions of the role of the pharmaceutical industry in drug development. Data were collected in January 2021 from a quota sample of the French population aged 18–75 years (N = 1,000) during the second round of the "Health Literacy Survey 2019" (HLS19). We tested the hypothesis that individuals with a high level of familiarity with the health care system and those with a high level of trust in institutions are more likely to agree that new drugs are more effective than old ones and that drug development should be driven by the pharmaceutical industry. A quarter (25%) of respondents agreed that new drugs are always more effective than old ones. Agreement with this statement was stronger among respondents with a high level of familiarity with the health care system (as measured by the Navigational Health Literacy score, OR 3.34 [2.13-5.24]) and among those with a high level of trust in pharmaceutical companies or politicians. A high level of trust in pharmaceutical companies was reported by 42% of respondents, and 43% agreed that drug development should be driven by the pharmaceutical industry. Respondents who agreed that new drugs are always more effective than old ones were almost four times more likely to agree that drug development should be driven by the pharmaceutical industry (OR 3.85 [2.76-5.39]). A better understanding of public attitudes towards new treatments is needed to elucidate individual preferences in health care and their consequences on health behavior.

During the COVID-19 pandemic, public debates overtly addressed the promises of new innovative treatments. Many of these debates pitted those who advocated for the development of new treatments by pharmaceutical companies against those who favored the repositioning of existing drugs. Our study explored perceptions of the association between drug novelty and effectiveness as well as perceptions of the role of the pharmaceutical industry in drug development. Data were collected in January 2021 from a quota sample of the French population aged 18–75 years (N = 1,000) during the second round of the "Health Literacy Survey 2019" (HLS19). We tested the hypothesis that individuals with a high level of familiarity with the health care system and those with a high level of trust in institutions are more likely to agree that new drugs are more effective than old ones and that drug development should be driven by the pharmaceutical industry. A quarter (25%) of respondents agreed that new drugs are always more effective than old ones. Agreement with this statement was stronger among respondents with a high level of familiarity with the health care system (as measured by the Navigational Health Literacy score, OR 3.34 [2.13-5.24]) and among those with a high level of trust in pharmaceutical companies or politicians. A high level of trust in pharmaceutical companies was reported by 42% of respondents, and 43% agreed that drug development should be driven by the pharmaceutical industry. Respondents who agreed that new drugs are always more effective than old ones were almost four times more likely to agree that drug development should be driven by the pharmaceutical industry (OR 3.85 [2.76-5.39]). A better understanding of public attitudes towards new treatments is needed to elucidate individual preferences in health care and their consequences on health behavior.

During the COVID-19 pandemic, public debates overtly addressed the promises of new innovative treatments. Many of these debates pitted those who advocated for the development of new treatments by pharmaceutical companies against those who favored the repositioning of existing drugs. Our study explored perceptions of the association between drug novelty and effectiveness as well as perceptions of the role of the pharmaceutical industry in drug development. Data were collected in January 2021 from a quota sample of the French population aged 18–75 years (N = 1,000) during the second round of the "Health Literacy Survey 2019" (HLS19). We tested the hypothesis that individuals with a high level of familiarity with the health care system and those with a high level of trust in institutions are more likely to agree that new drugs are more effective than old ones and that drug development should be driven by the pharmaceutical industry. A quarter (25%) of respondents agreed that new drugs are always more effective than old ones. Agreement with this statement was stronger among respondents with a high level of familiarity with the health care system (as measured by the Navigational Health Literacy score, OR 3.34 [2.13-5.24]) and among those with a high level of trust in pharmaceutical companies or politicians. A high level of trust in pharmaceutical companies was reported by 42% of respondents, and 43% agreed that drug development should be driven by the pharmaceutical industry. Respondents who agreed that new drugs are always more effective than old ones were almost four times more likely to agree that drug development should be driven by the pharmaceutical industry (OR 3.85 [2.76-5.39]). A better understanding of public attitudes towards new treatments is needed to elucidate individual preferences in health care and their consequences on health behavior.